Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
Kosuke TakemuraVishal NavaniMatthew S ErnstJ Connor WellsLuis MezaSumanta K PalJae-Lyun LeeHaoran LiNeeraj AgarwalAjjai S AlvaAaron R HansenNaveen S BasappaBernadett SzabadosThomas PowlesBen TranChristopher M HockingBenoit BeuselinckTakeshi YuasaToni K ChoueiriDaniel Y C HengPublished in: The Journal of urology (2022)
The complete response rate was not as high in the real-world population as in the clinical trial population. Among those who experienced complete response, several adverse clinicopathological features were more frequently observed in the immuno-oncology-based cohort than in the tyrosine kinase inhibitor cohort. Complete response was an indicator of favorable overall survival.